Clinical Trial Results:
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 5PSP for the Treatment of HPV-16 and/or HPV-18 Related High-Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
Summary
|
|
EudraCT number |
2016-002761-63 |
Trial protocol |
GB LT FI DE CZ ES PT PL SK BE NL EE IT |
Global end of trial date |
06 Apr 2021
|
Results information
|
|
Results version number |
v1 |
This version publication date |
27 May 2022
|
First version publication date |
27 May 2022
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
HPV-301
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT03185013 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
US IND Number: 13683 | ||
Sponsors
|
|||
Sponsor organisation name |
Inovio Pharmaceuticals, Inc.
|
||
Sponsor organisation address |
660 W. Germantown Pike, Suite 110, Plymouth Meeting, United States, PA 19462
|
||
Public contact |
Clinical Development, Inovio Pharmaceuticals, Inc., HPV301ClinicalTeam@inovio.com
|
||
Scientific contact |
Clinical Development, Inovio Pharmaceuticals, Inc., HPV301ClinicalTeam@inovio.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
03 Mar 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
06 Apr 2021
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Apr 2021
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
Determine the efficacy of VGX-3100 compared with placebo with respect to combined histopathologic regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18
|
||
Protection of trial subjects |
This protocol was implemented in accordance with the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use harmonised tripartite guideline E6(R2): Good Clinical Practice. Written informed consent was to be obtained from each subject and/or from the subject’s legally authorized representative prior to screening into the clinical trial. Subjects were asked to complete a participant diary card during their clinical trial participation to record local and systemic adverse events for 7 days after each clinical trial treatment. Subjects were provided with the investigator emergency contact information and advised to report all AEs.
|
||
Background therapy |
Subjects might have used supportive medications for management of anxiety and pain due to treatment (topical anesthetic, mild sedative, analgesic). | ||
Evidence for comparator |
Placebo (150 mM sodium chloride and 15 mM sodium citrate) plus EP (electroporation) with CELLECTRA™ 5PSP. | ||
Actual start date of recruitment |
28 Jun 2017
|
||
Long term follow-up planned |
Yes
|
||
Long term follow-up rationale |
Safety, Efficacy | ||
Long term follow-up duration |
88 Months | ||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Argentina: 4
|
||
Country: Number of subjects enrolled |
Mexico: 1
|
||
Country: Number of subjects enrolled |
Peru: 2
|
||
Country: Number of subjects enrolled |
Philippines: 1
|
||
Country: Number of subjects enrolled |
South Africa: 16
|
||
Country: Number of subjects enrolled |
Thailand: 12
|
||
Country: Number of subjects enrolled |
United States: 56
|
||
Country: Number of subjects enrolled |
Poland: 7
|
||
Country: Number of subjects enrolled |
Portugal: 6
|
||
Country: Number of subjects enrolled |
Slovakia: 6
|
||
Country: Number of subjects enrolled |
Spain: 13
|
||
Country: Number of subjects enrolled |
United Kingdom: 3
|
||
Country: Number of subjects enrolled |
Belgium: 4
|
||
Country: Number of subjects enrolled |
Estonia: 36
|
||
Country: Number of subjects enrolled |
Finland: 5
|
||
Country: Number of subjects enrolled |
Germany: 3
|
||
Country: Number of subjects enrolled |
Italy: 4
|
||
Country: Number of subjects enrolled |
Lithuania: 22
|
||
Worldwide total number of subjects |
201
|
||
EEA total number of subjects |
106
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
201
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||||||||||||||||||||
Recruitment
|
||||||||||||||||||||||||||||||||||
Recruitment details |
A total of 201 subjects were randomly assigned to receive either VGX-3100 + EP (138 subjects) or placebo + EP (63 subjects) within 10 weeks of first dose of clinical trial treatment (Day 0). | |||||||||||||||||||||||||||||||||
Pre-assignment
|
||||||||||||||||||||||||||||||||||
Screening details |
All screening evaluations were to be completed within 10 weeks of first dose of clinical trial treatment (Day 0), except for the safety laboratory assessments, which were to be performed within 45 days prior to Day 0. | |||||||||||||||||||||||||||||||||
Period 1
|
||||||||||||||||||||||||||||||||||
Period 1 title |
Treatment Period (overall period)
|
|||||||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||||||||||||||||||||
Blinding used |
Double blind | |||||||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer | |||||||||||||||||||||||||||||||||
Blinding implementation details |
This clinical trial was double-blinded with blinding maintained throughout the clinical trial by use of identical packaging for both the active product VGX-3100 and the placebo. There was no difference in appearance for both the active product and the placebo. No personnel directly involved with the clinical trial was to be unblinded. The investigator may have requested to unblind a subject’s treatment assignment in case of an emergency or serious medical condition.
|
|||||||||||||||||||||||||||||||||
Arms
|
||||||||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||||||||||||||||||||
Arm title
|
VGX-3100 + EP | |||||||||||||||||||||||||||||||||
Arm description |
Eligible subjects received three 6-mg doses of VGX-3100 refrigerated formulation provided as a solution followed immediately by electroporation (EP) with the CELLECTRA™ 5PSP device. Treatment was administered over 12 weeks. | |||||||||||||||||||||||||||||||||
Arm type |
Experimental | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
VGX-3100
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Injection , Intramuscular use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
6-mg dose of VGX-3100 drug product was delivered IM followed by EP. VGX-3100 drug product was provided as a solution containing 6 mg in 150 mM sodium chloride and 15 mM sodium citrate. The IP was delivered using the CELLECTRA™ 5PSP device. The device consisted of the following components: 1) Base Station; 2) Handset; and 3) Sterile single-use Array (for accepting the IP cartridge). The first clinical trial treatment was administered on Day 0, the second at Week 4, and the third (final) at Week 12.
|
|||||||||||||||||||||||||||||||||
Arm title
|
Placebo + EP | |||||||||||||||||||||||||||||||||
Arm description |
Eligible subjects received three placebo, followed immediately by electroporation (EP) with the CELLECTRA™ 5PSP device. Treatment was administered over 12 weeks. | |||||||||||||||||||||||||||||||||
Arm type |
Placebo + EP | |||||||||||||||||||||||||||||||||
Investigational medicinal product name |
Placebo
|
|||||||||||||||||||||||||||||||||
Investigational medicinal product code |
||||||||||||||||||||||||||||||||||
Other name |
||||||||||||||||||||||||||||||||||
Pharmaceutical forms |
Solution for injection
|
|||||||||||||||||||||||||||||||||
Routes of administration |
Injection , Intramuscular use
|
|||||||||||||||||||||||||||||||||
Dosage and administration details |
Subjects received 1 mL placebo IM followed by EP. Placebo was delivered using the CELLECTRA™ 5PSP device. The device consisted of the following components: 1) Base Station; 2) Handset; and 3) Sterile single-use Array (for accepting the IP cartridge). The first clinical trial treatment was administered on Day 0, the second at Week 4, and the third (final) at Week 12.
|
|||||||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
VGX-3100 + EP
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Eligible subjects received three 6-mg doses of VGX-3100 refrigerated formulation provided as a solution followed immediately by electroporation (EP) with the CELLECTRA™ 5PSP device. Treatment was administered over 12 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo + EP
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Eligible subjects received three placebo, followed immediately by electroporation (EP) with the CELLECTRA™ 5PSP device. Treatment was administered over 12 weeks. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Intent-to-Treat (ITT)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Intent-to-Treat (ITT) set included all subjects who were randomized. Subjects in this sample were grouped to treatment as randomized. The ITT set was used for the primary analysis of efficacy in this clinical trial.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Modified ITT (mITT)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Modified intention-to-treat | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Modified Intent-to-Treat (mITT) Set included all subjects who received at least one (1) dose of clinical trial treatment and who had the analysis endpoint of interest. Subjects in this sample were grouped to treatment as randomized. Analysis of the mITT set was considered supportive for the corresponding ITT set for the analysis of efficacy. The analysis of the mITT set also served as sensitivity analyses regarding missing data.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Per-Protocol (PP) Set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Per protocol | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
Per-Protocol (PP) Set was comprised of subjects who received all doses of clinical trial treatments, had no protocol violations, and had the analysis endpoint of interest. Subjects in this sample were grouped to treatment as randomized. Analyses on the PP set was considered supportive of the corresponding ITT set for the analysis of efficacy. The analysis of PP Set also served as sensitivity analyses regarding early intervention (i.e, intervention before the Week 36 timeframe).
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
Safety Set
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Safety analysis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
The safety set included all subjects who received at least one (1) dose of clinical trial treatment. Subjects were analyzed as to the treatment they actually received.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
VGX-3100 + EP
|
||
Reporting group description |
Eligible subjects received three 6-mg doses of VGX-3100 refrigerated formulation provided as a solution followed immediately by electroporation (EP) with the CELLECTRA™ 5PSP device. Treatment was administered over 12 weeks. | ||
Reporting group title |
Placebo + EP
|
||
Reporting group description |
Eligible subjects received three placebo, followed immediately by electroporation (EP) with the CELLECTRA™ 5PSP device. Treatment was administered over 12 weeks. | ||
Subject analysis set title |
Intent-to-Treat (ITT)
|
||
Subject analysis set type |
Intention-to-treat | ||
Subject analysis set description |
Intent-to-Treat (ITT) set included all subjects who were randomized. Subjects in this sample were grouped to treatment as randomized. The ITT set was used for the primary analysis of efficacy in this clinical trial.
|
||
Subject analysis set title |
Modified ITT (mITT)
|
||
Subject analysis set type |
Modified intention-to-treat | ||
Subject analysis set description |
Modified Intent-to-Treat (mITT) Set included all subjects who received at least one (1) dose of clinical trial treatment and who had the analysis endpoint of interest. Subjects in this sample were grouped to treatment as randomized. Analysis of the mITT set was considered supportive for the corresponding ITT set for the analysis of efficacy. The analysis of the mITT set also served as sensitivity analyses regarding missing data.
|
||
Subject analysis set title |
Per-Protocol (PP) Set
|
||
Subject analysis set type |
Per protocol | ||
Subject analysis set description |
Per-Protocol (PP) Set was comprised of subjects who received all doses of clinical trial treatments, had no protocol violations, and had the analysis endpoint of interest. Subjects in this sample were grouped to treatment as randomized. Analyses on the PP set was considered supportive of the corresponding ITT set for the analysis of efficacy. The analysis of PP Set also served as sensitivity analyses regarding early intervention (i.e, intervention before the Week 36 timeframe).
|
||
Subject analysis set title |
Safety Set
|
||
Subject analysis set type |
Safety analysis | ||
Subject analysis set description |
The safety set included all subjects who received at least one (1) dose of clinical trial treatment. Subjects were analyzed as to the treatment they actually received.
|
|
|||||||||||||||||||
End point title |
Histopathological Regression of Cervical HSIL and Virologic Clearance of HPV-16 and/or HPV-18 at Week 36 (ITT Population) | ||||||||||||||||||
End point description |
The percentage of responders in each treatment group was based on the histopathological regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 at Week 36 and it was summarized for the ITT Population.
|
||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||
End point timeframe |
At Week 36
|
||||||||||||||||||
|
|||||||||||||||||||
Statistical analysis title |
Statistical Analysis | ||||||||||||||||||
Statistical analysis description |
A p-value of superiority based on a test of risk difference and corresponding 95% confidence interval (CI) using the method of Miettinen and Nurminen were computed. Superiority was concluded if the one-sided p-value was <0.025 and the corresponding lower bound of the 95% CI exceeded zero (0).
|
||||||||||||||||||
Comparison groups |
VGX-3100 + EP v Placebo + EP
|
||||||||||||||||||
Number of subjects included in analysis |
201
|
||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||
P-value |
= 0.029 [1] | ||||||||||||||||||
Method |
Miettinen and Nurminen | ||||||||||||||||||
Parameter type |
Risk difference (RD) | ||||||||||||||||||
Point estimate |
11.4
|
||||||||||||||||||
Confidence interval |
|||||||||||||||||||
level |
95% | ||||||||||||||||||
sides |
2-sided
|
||||||||||||||||||
lower limit |
-0.4 | ||||||||||||||||||
upper limit |
21.2 | ||||||||||||||||||
Notes [1] - One-sided p-value |
|
||||||||||||||||||||||
End point title |
Histopathological Regression of Cervical HSIL and Virologic Clearance of HPV-16 and/or HPV-18 at Week 36 (mITT Population) | |||||||||||||||||||||
End point description |
The percentage of responders in each treatment group was based on the histopathological regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 at Week 36 and it was summarized for the mITT population. Analyses of primary efficacy endpoint with the mITT set served as sensitivity analyses and were considered supportive of the corresponding analysis with the ITT set.
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
At Week 36
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Statistical Analysis | |||||||||||||||||||||
Statistical analysis description |
A p-value of superiority was based on a test of risk difference and corresponding 95% CI using the method of Miettinen and Nurminen. Superiority was concluded if the one-sided p-value was <0.025 and the corresponding lower bound of the 95% CI exceeded zero (0).
|
|||||||||||||||||||||
Comparison groups |
VGX-3100 + EP v Placebo + EP
|
|||||||||||||||||||||
Number of subjects included in analysis |
197
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority | |||||||||||||||||||||
P-value |
= 0.022 [2] | |||||||||||||||||||||
Method |
Miettinen and Nurminen | |||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||
Point estimate |
12.4
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.4 | |||||||||||||||||||||
upper limit |
22.5 | |||||||||||||||||||||
Notes [2] - One-sided p-value |
|
||||||||||||||||||||||
End point title |
Histopathological Regression of Cervical HSIL and Virologic Clearance of HPV-16 and/or HPV-18 at Week 36 (PP Population) | |||||||||||||||||||||
End point description |
The percentage of responders in each treatment group was based on the histopathological regression of cervical HSIL and virologic clearance of HPV-16 and/or HPV-18 at Week 36 and it was summarized for the PP Population. Analyses of primary efficacy endpoint with the PP set served as sensitivity analyses and were considered supportive of the corresponding analysis with the ITT set.
|
|||||||||||||||||||||
End point type |
Primary
|
|||||||||||||||||||||
End point timeframe |
At Week 36
|
|||||||||||||||||||||
|
||||||||||||||||||||||
Statistical analysis title |
Statistical Analysis | |||||||||||||||||||||
Statistical analysis description |
A p-value of superiority was based on a test of risk difference and corresponding 95% CI using the method of Miettinen and Nurminen. Superiority was concluded if the one-sided p-value was <0.025 and the corresponding lower bound of the 95% CI exceeded zero (0).
|
|||||||||||||||||||||
Comparison groups |
Placebo + EP v VGX-3100 + EP
|
|||||||||||||||||||||
Number of subjects included in analysis |
184
|
|||||||||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||||||||
Analysis type |
superiority | |||||||||||||||||||||
P-value |
= 0.021 [3] | |||||||||||||||||||||
Method |
Miettinen and Nurminen | |||||||||||||||||||||
Parameter type |
Risk difference (RD) | |||||||||||||||||||||
Point estimate |
12.9
|
|||||||||||||||||||||
Confidence interval |
||||||||||||||||||||||
level |
95% | |||||||||||||||||||||
sides |
2-sided
|
|||||||||||||||||||||
lower limit |
0.5 | |||||||||||||||||||||
upper limit |
23.5 | |||||||||||||||||||||
Notes [3] - One-sided p-value |
|
|||||||||||||||||||||||||||||||||||||||||||
End point title |
Overview of Adverse Events (Safety Population) | ||||||||||||||||||||||||||||||||||||||||||
End point description |
Treatment-Emergent Adverse Events (TEAE) was defined as AE with onset date on or after clinical trial treatment. One subject excluded due to receiving mixed treatment.
|
||||||||||||||||||||||||||||||||||||||||||
End point type |
Secondary
|
||||||||||||||||||||||||||||||||||||||||||
End point timeframe |
With onset date on or after clinical trial treatment
|
||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Onset date on or after clinical trial treatment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse event reporting additional description |
Treatment-Emergent Adverse Events (TEAE) was defined as AE with onset date on or after clinical trial treatment. One subject excluded due to receiving mixed treatment.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
24.0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
VGX-3100 + EP
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Eligible subjects received three 6-mg doses of VGX-3100 refrigerated formulation followed immediately by electroporation (EP) with the CELLECTRA™ 5PSP device. The first clinical trial treatment was administered on Day 0, the second at Week 4, and the third (final) at Week 12. The first clinical trial treatment was given as soon as possible following confirmation of the cervical HSIL diagnosis and HPV-16 and/or HPV-18 status but no more than 10 weeks following collection of the subject’s biopsy specimen used for diagnosis by the PAC during screening, contemporaneous with the positive testing for HPV-16 and/or HPV-18. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Placebo + EP
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Eligible subjects received three placebo, followed immediately by electroporation (EP) with the CELLECTRA™ 5PSP device. The first clinical trial treatment was administered on Day 0, the second at Week 4, and the third (final) at Week 12. The first clinical trial treatment was given as soon as possible following confirmation of the cervical HSIL diagnosis and HPV-16 and/or HPV-18 status but no more than 10 weeks following collection of the subject’s biopsy specimen used for diagnosis by the PAC during screening, contemporaneous with the positive testing for HPV-16 and/or HPV-18. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
06 Jun 2016 |
The main changes in Protocol version 2.0 include the following:
• Added rationale for selection of nonfrozen formulation for Phase 3 clinical trial.
• Added additional background information to Section 2 Study Design.
• Clarified inclusion and exclusion criteria.
• Administrative changes made throughout the protocol for clarification, that did not significantly affect the safety of subjects, clinical trial scope, or scientific quality of the protocol.
|
||
10 Jun 2016 |
The main changes in Protocol version 2.1 include the following:
• Administrative and formatting changes were made to protocol version 2.0 dated 06Jun2016 resulting in protocol version 2.1 dated 10Jun2016. |
||
23 Sep 2016 |
The main changes in Protocol version 3.0 include the following:
• Name of the investigational product (IP) was changed from VGX-3100X to VGX-3100. The term VGX-3100 as used in protocol version 3.0 denoted 3.0 ± 0.2 mg/mL pGX3001 bulk plasmid and 3.0 ± 0.2 mg/mL pGX3002 bulk plasmid in SSC buffer, refrigerated formulation.
• The population for the primary analysis for the clinical trial was changed from mITT based on complete data to intent-to-treat (ITT) analysis. Based on this change, the number of subjects to be enrolled in the clinical trial was now 198 instead of 165.
• Modifications in objectives and endpoints
• Modifications in inclusion and exclusion criteria
• Modifications to the clinical trial evaluations
• Section 2.1.3 Definition of Responder and Nonresponde
• Added information on supplementation of subjects in case more than 10% of subjects randomly assigned to clinical trial treatment discontinued prior to the Week 36 primary endpoint procedure.
• Section 5.7 Return and Destruction of Investigational Product
• Section 6.1.1 Screening Evaluations
• Section 6.15.1 Prohibited Concomitant Medications and Treatments
• Added that progression of HSIL to microinvasive or invasive squamous cell carcinoma should be reported as an SAE.
• Section 7.3.1 was modified to replace the term “events requiring expedited reporting” to “adverse events of special interest (AESI)”. Added clarification on reporting requirements to sponsor.
• Section 7.4.2 was updated to reflect change in reporting contact details in event of SAE.
• Section 8 Statistical Analysis section
• Section 9.4.2 Pathology Adjudication Committee
• Additional administrative clarifications were made to the protocol that did not significantly affect the safety of subjects, clinical trial scope, or scientific quality of the protocol. |
||
29 Mar 2018 |
The main changes in Protocol version 4.0 include the following:
• Modifications and updates to the hypothesis, objectives, and endpoints
• Revisions to the inclusion and exclusion criteria
• Updates were made to the Schedule of Events table to align with the protocol text and above-mentioned changes to the clinical trial endpoints and inclusion and exclusion criteria.
• General updates and clarifications
• Section 7.3 (Safety and Toxicity Management) was modified to align with safety assessments as stated in the section describing clinical trial design of clinical protocol synopsis.
• Section 8 (Statistical Analysis Plan) was revised to align with the changes made to objectives and endpoints.
• Section 9.4.2 (Pathology Adjudication Committee) was modified to refer to the PAC charter, which had the most current information regarding the PAC review process.
• The PDC was unchanged but was removed from the Appendix since the PDC was a separate document.
• Additional minor grammatical and administrative changes were made throughout the document for improving the general readability of the protocol.
|
||
20 Nov 2019 |
The main changes in Protocol version 5.0 include the following:
• Human leukocyte antigen (HLA) testing and associated exploratory endpoint 2 was removed from the protocol in consideration of the HPV-003 clinical trial results which showed no clear association of HLA background as a predictor of response.
• Group-level unblinded (VGX-3100, placebo) summaries and analyses of efficacy were to be produced once the primary endpoint Week 36 visit data were collected for all subjects.
• The stopping rules outlined in Section 7.3.2, Stopping Rules (Criteria for Pausing of Study), were clarified to focus on unexpected, verified events and not include events that were already described as known adverse drug reactions.
• Additional administrative clarifications were made to the protocol that did not significantly affect the safety of subjects, clinical trial scope, or scientific quality of the protocol. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |